Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Nanomedicine and Nanoscale Delivery (Focus Group – NND)

Aptamer-Targeted Lipid Nanoparticles for Immunotherapeutics delivery for glioblastoma

Khuloud Al-Jamal – Professor, Hong Kong univerisity; Alexandra Paul – Post-Doc, Hong Kong univerisity
Introduction:

Glioblastoma (GB) is the most lethal brain tumour, where the blood-brain barrier (BBB) and an immunosuppressive environment render standard therapies ineffective. While immunotherapies are promising, systemic delivery lacks specificity, leading to off-target toxicity and suboptimal therapeutic concentrations at the tumour site. To address this, we developed an Aptamer-Targeted Lipid Nanoparticle (Apt-LNP) platform that utilises synthetic single-stranded oligonucleotides. These LNPs recognise specific GB biomarkers to facilitate receptor-mediated transcytosis across the BBB, enabling precise drug delivery and enhanced therapeutic efficacy.

Learning Objectives:

  • Understand the correlation between the uptake kinetics of Apt-LNP and transfection efficiency in target cells.
  • Explain the benefits of AAO nanofiltration over traditional methods for high LNP recovery and ligand removal.
  • Evaluate Design of Experiments (DoE) role in optimising LNPs compositions for targets like BMDCs and GL261 cells.